This announcement is a separate document:
神州细胞自愿披露关于控股子公司重组带状疱疹疫苗SCTV04C获得药物临床试验批准通知书的公告
Shenzhou Cell voluntarily disclosed an announcement that its holding subsidiary SCTV04C obtained a notice of approval for drug clinical trials of the recombinant shingles vaccine
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.